Publications

2019

Green, C., R. Handels, A. Gustavsson, A. Wimo, B. Winblad, A. Skoldunger and L. Jonsson (2019). “Assessing cost-effectiveness of early intervention in Alzheimer’s disease: An open-source modeling framework.” Alzheimers Dement.

Hansson-Hedblom, A., E. Jonsson, P. Fritzell, O. Hagg and F. Borgstrom (2019). “The Association Between Patient Reported Outcomes of Spinal Surgery and Societal Costs: A Register Based Study.” Spine (Phila Pa 1976) 44(18): 1309-1317.

Iderberg H, Willers C, Borgstrom F, Hedlund R, Hagg O, Moller H, et al. “Predicting clinical outcome and length of sick leave after surgery for lumbar spinal stenosis in Sweden: a multi-register evaluation.” Eur Spine J. 2019;28(6):1423-32.

Kanis JA, Johansson H, Harvey NC, Lorentzon M, Liu E, Borgstrom F, et al. “Correspondence in response to OSIN-D-18-00831 quantifying imminent risk.” Osteoporos Int. 2019;30(2):525-6.

Ortsater G, Borgstrom F, Soulard S, Miltenburger C. A “Budget Impact Model to Estimate the Environmental Impact of Adopting RESPIMAT((R)) Re-usable in the Nordics and Benelux.” Adv Ther. 2019.

Tatangelo G, Watts J, Lim K, Connaughton C, Abimanyi-Ochom J, Borgstrom F, et al. “The Cost of Osteoporosis, Osteopenia, and Associated Fractures in Australia in 2017.” J Bone Miner Res. 2019;34(4):616-25.

Tochel C, Smith M, Baldwin H, Gustavsson A, Ly A, Bexelius C, et al. “What outcomes are important to patients with mild cognitive impairment or Alzheimer’s disease, their caregivers, and health-care professionals? A systematic review.” Alzheimers Dement (Amst).

Lauppe R, Akesson KE, Ljunggren O, Spangeus A, Ortsater G, Feudjo-Tepie M and Strom, O. Differing impact of clinical factors on the risk of fracture in younger and older women in the general population and an osteoporosis clinic population. Arch Osteoporos.

Lindh, M., J. Banefelt, K-M. Fox, S. Hallberg, M-H. Tai, M. Eriksson, G. Villa, M-K. Svensson, and Y. Qian (2019). “Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population–estimates from Swedish population-based register data.” European Heart Journal – Quality of Care and Clinical Outcomes.

Grip, E. T., Svensson, A. M., Miftaraj, M., Eliasson, B., Franzén, S., Gudbjörnsdottir, S., & Carlsson, K. S. (2019). Real-World Costs of Continuous Insulin Pump Therapy and Multiple Daily Injections for Type 1 Diabetes: A Population-Based and Propensity-Matched Cohort From the Swedish National Diabetes Register. Diabetes care, 42(4), 545-552.

Banefelt, J., K-E. Åkesson, A. Spångéus, O. Ljunggren, L. Karlsson, O. Ström, G. Ortsäter, C. Libanati, and E. Toth (2019). “Risk of imminent fracture following a previous fracture in a Swedish database study.” Osteoporosis International.

2018

Rudberg, A-S., E. Berge, A. Gustavsson, P. Näsman, and E. Lundström (2018). “Long-term health-related quality of life, survival and costs by different levels of functional outcome six months after stroke.” European Stroke Journal.

Guirant, L., F. Carlos, D. Curiel, J. A. Kanis, F. Borgstrom, A. Svedbom and P. Clark (2018). “Health-related quality of life during the first year after a hip fracture: results of the Mexican arm of the International Cost and Utility Related to Osteoporotic Fractures Study (MexICUROS).” Osteoporos Int 29(5): 1147-1154.

Hansson-Hedblom, A., C. Almond, F. Borgstrom, I. Sly, D. Enkusson, A. Troelsgaard Buchholt and L. Karlsson (2018). “Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden.” Cost Eff Resour Alloc 16: 28.

Jonsson, E., A. Hansson-Hedblom, O. Ljunggren, K. Akesson, A. Spangeus, J. A. Kanis and F. Borgstrom (2018). “A health economic simulation model for the clinical management of osteoporosis.” Osteoporos Int 29(3): 545-555.

Kanis, J. A., H. Johansson, A. Oden, N. C. Harvey, V. Gudnason, K. M. Sanders, G. Sigurdsson, K. Siggeirsdottir, L. A. Fitzpatrick, F. Borgstrom and E. V. McCloskey (2018). “Characteristics of recurrent fractures.” Osteoporos Int 29(8): 1747-1757.

Luthman, S., J. Widen and F. Borgstrom (2018). “Appropriateness criteria for treatment of osteoporotic vertebral compression fractures.” Osteoporos Int 29(4): 793-804.

Olafsson, G., E. Jonsson, P. Fritzell, O. Hagg and F. Borgstrom (2018). “Cost of low back pain: results from a national register study in Sweden.” Eur Spine J.

Svedbom, A., F. Borgstrom, E. Hernlund, O. Strom, V. Alekna, M. L. Bianchi, P. Clark, M. D. Curiel, H. P. Dimai, M. Jurisson, A. Uuskula, M. Lember, R. Kallikorm, O. Lesnyak, E. McCloskey, O. Ershova, K. M. Sanders, S. Silverman, M. Tamulaitiene, T. Thomas, A. N. A. Tosteson, B. Jonsson and J. A. Kanis (2018). “Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS.” Qual Life Res 27(3): 707-716.

2017

Eriksson, D., L. Karlsson, O. Eklund, H. Dieperink, E. Honkanen, J. Melin, K. Selvig and J. Lundberg (2017). “Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.” BMC Health Serv Res 17(1): 560.

Guo, Q., S. Burgess, C. Turman, M. K. Bolla, Q. Wang, M. Lush, J. Abraham, K. Aittomaki, I. L. Andrulis, C. Apicella, V. Arndt, M. Barrdahl, J. Benitez, C. D. Berg, C. Blomqvist, S. E. Bojesen, B. Bonanni, J. S. Brand, H. Brenner, A. Broeks, B. Burwinkel, C. Caldas, D. Campa, F. Canzian, J. Chang-Claude, S. J. Chanock, S. F. Chin, F. J. Couch, A. Cox, S. S. Cross, C. Cybulski, K. Czene, H. Darabi et al., and P. D. P. Pharoah (2017). “Body mass index and breast cancer survival: a Mendelian randomization analysis.” Int J Epidemiol 46(6): 1814-1822.

Gustavsson, A., C. Green, R. W. Jones, H. Forstl, D. Simsek, F. de Reydet de Vulpillieres, S. Luthman, N. Adlard, S. Bhattacharyya and A. Wimo (2017). “Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer’s disease.” Alzheimers Dement 13(3): 312-321.

Jonsson, E., G. Olafsson, P. Fritzell, O. Hagg and F. Borgstrom (2017). “Profile of Low Back Pain: Treatment and Costs Associated With Patients Referred to Orthopaedic Specialists in Sweden.” Spine (Phila Pa 1976).

Karlsson, L., J. Mesterton, M. F. Tepie, M. Intorcia, J. Overbeek and O. Strom (2017). “Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.” Arch Osteoporos 12(1): 81.

Milne, R. L, H. Darabi, et al. and J. Simard (2017). “Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.” Nat Genet 49(12): 1767-1778.

Olafsson, G., E. Jonsson, P. Fritzell, O. Hagg and F. Borgstrom (2017). “A health economic lifetime treatment pathway model for low back pain in Sweden.” J Med Econ: 1-18.

Svedbom, A., F. Borgstom, E. Hernlund, O. Strom, V. Alekna, M. L. Bianchi, P. Clark, M. D. Curiel, H. P. Dimai, M. Jurisson, R. Kallikorm, M. Lember, O. Lesnyak, E. McCloskey, K. M. Sanders, S. Silverman, A. Solodovnikov, M. Tamulaitiene, T. Thomas, N. Toroptsova, A. Uuskula, A. N. A. Tosteson, B. Jonsson and J. A. Kanis (2017). “Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS.” Osteoporos Int.

Svedbom, A., F. Borgstrom, E. Hernlund, O. Strom, V. Alekna, M. L. Bianchi, P. Clark, M. D. Curiel, H. P. Dimai, M. Jurisson, A. Uuskula, M. Lember, R. Kallikorm, O. Lesnyak, E. McCloskey, O. Ershova, K. M. Sanders, S. Silverman, M. Tamulaitiene, T. Thomas, A. N. A. Tosteson, B. Jonsson and J. A. Kanis (2017). “Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS.” Qual Life Res.

2016

Banefelt, J., S. Hallberg, K. M. Fox, J. Mesterton, C. J. Paoli, G. Johansson, L. A. Levin, P. Sobocki and S. R. Gandra (2016). “Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden.” Eur J Health Econ 17(9): 1117-1124.

Bergqvist, J., H. Iderberg, J. Mesterton, N. Bengtsson, B. Wettermark and R. Henriksson (2016). “Healthcare resource use, comorbidity, treatment and clinical outcomes for patients with primary intracranial tumors: a Swedish population-based register study.” Acta Oncol: 1-10.

Darabi, H., J. Beesley, A. Droit, S. Kar, S. Nord, M. Moradi Marjaneh, P. Soucy, K. Michailidou, M. Ghoussaini, H. Fues Wahl et al., and A. M. Dunning (2016). “Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs).” Sci Rep 6: 32512.

Eklund, O., F. Afzal, F. Borgstrom, J. Flavin, A. Ternouth, M. E. Ojanguren, C. Crespo and M. Baldwin (2016). “Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK.” Clinicoecon Outcomes Res 8: 243-252.

Eriksson, D., D. Goldsmith, S. Teitsson, J. Jackson and F. van Nooten (2016). “Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia.” BMC Nephrol 17(1): 97.

Eriksson, D., L. Karlsson, O. Eklund, H. Dieperink, E. Honkanen, J. Melin, K. Selvig and J. Lundberg (2016). “Health-related quality of life across all stages of autosomal dominant polycystic kidney disease.” Nephrol Dial Transplant.

Hallberg, S., J. Banefelt, K. M. Fox, J. Mesterton, G. Johansson, L. A. Levin, P. Sobocki and S. R. Gandra (2016). “Lipid-lowering treatment patterns in patients with new cardiovascular events – estimates from population-based register data in Sweden.” Int J Clin Pract 70(3): 222-228.

Hallberg, S., S. R. Gandra, K. M. Fox, J. Mesterton, J. Banefelt, G. Johansson, L. A. Levin and P. Sobocki (2016). “Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data.” Eur J Health Econ 17(5): 591-601.

Jurisson, M., H. Pisarev, J. Kanis, F. Borgstrom, A. Svedbom, R. Kallikorm, M. Lember and A. Uuskula (2016). “Quality of life, resource use, and costs related to hip fracture in Estonia.” Osteoporos Int 27(8): 2555-2566.

Marques, A., O. Lourenco, G. Ortsater, F. Borgstrom, J. A. Kanis and J. A. da Silva (2016). “Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(R) in Portugal.” Calcif Tissue Int.

Mesterton, J., P. Lindgren, A. Ekenberg Abreu, L. Ladfors, M. Lilja, S. Saltvedt and I. Amer-Wahlin (2016). “Case mix adjustment of health outcomes, resource use and process indicators in childbirth care: a register-based study.” BMC Pregnancy Childbirth 16(1): 125.

Wimo, A., L. Jonsson, L. Fratiglioni, P. O. Sandman, A. Gustavsson, A. Skoldunger and L. Johansson (2016). “The societal costs of dementia in Sweden 2012 – relevance and methodological challenges in valuing informal care.” Alzheimers Res Ther 8(1): 59.

Wohlin, J., H. Stalberg, O. Ström, O. Rolfson, C. Willers and M. Brommels (2016). Effects of introducing bundled payment and patients’ choice of provider for elective hip and knee replacements in Stockholm county. public report. http://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2016/11/Ny-modell-forbattrar-varden-for-hoft–och-knapatienter/, Department of Learning, Informatics, Management and Ethics.

2015

Abimanyi-Ochom, J., J. J. Watts, F. Borgstrom, G. C. Nicholson, C. Shore-Lorenti, A. L. Stuart, Y. Zhang, S. Iuliano, E. Seeman, R. Prince, L. March, M. Cross, T. Winzenberg, L. L. Laslett, G. Duque, P. R. Ebeling and K. M. Sanders (2015). “Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS).” Osteoporos Int 26(6): 1781-1790.

Banefelt, J., S. Hallberg, K. M. Fox, J. Mesterton, C. J. Paoli, G. Johansson, L. A. Levin, P. Sobocki and S. R. Gandra (2015). “Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden.” Eur J Health Econ.

Borgstrom, F., D. P. Beall, S. Berven, S. Boonen, S. Christie, D. F. Kallmes, J. A. Kanis, G. Olafsson, A. J. Singer and K. Akesson (2015). “Health economic aspects of vertebral augmentation procedures.” Osteoporos Int 26(4): 1239-1249.

Darabi, H., K. McCue, J. Beesley, K. Michailidou, S. Nord, S. Kar, K. Humphreys, D. Thompson, M. Ghoussaini, M. K. Bolla, J. Dennis, Q. Wang, et al. (2015). “Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression.” Am J Hum Genet 97(1): 22-34.

Eklund, O., F. Afzal and F. Borgstrom (2015). “Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden.” Cost Eff Resour Alloc 13: 13.

Eklund, O., F. Afzal, F. Borgstrom, M. E. Ojanguren, C. Crespo and M. Baldwin (2015). “Cost-Effectiveness Of Tiotropium Vs Glycopyrronium In Moderate To Very Severe Copd In Spain.” Value Health 18(7): A501.

Eriksson, D., L. Karlsson, O. Eklund, H. Dieperink, E. Honkanen, J. Melin, K. Selvig and J. Lundberg (2015). “Autosomal Polycystic Kidney Disease (Adpkd): Costs And Resource Utilisation In The Nordic Countries.” Value Health 18(7): A513.

Jonsson, E., D. Eriksson, K. Akesson, O. Ljunggren, S. Salomonsson, F. Borgstrom and O. Strom (2015). “Swedish osteoporosis care.” Arch Osteoporos 10: 222.

Jonsson, E., G. Olafsson, P. Fritzell, O. Hagg and F. Borgstrom (2015). “Productivity Loss Due to Low Back Pain: Results from Swedish Registers.” Value Health 18(7): A649.

Karlsson, L., J. Lundkvist, E. Psachoulia, M. Intorcia and O. Strom (2015). “Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis.” Osteoporos Int 26(10): 2401-2411.

Olafsson, G., E. Jonsson, P. Fritzell, O. Hagg and F. Borgstrom (2015). “Burden of Spinal Diseases: Results From Register Study In Sweden.” Value Health 18(7): A642.

Strom, O., E. Landfeldt and G. Garellick (2015). “Residual effect after oral bisphosphonate treatment and healthy adherer effects–the Swedish Adherence Register Analysis (SARA).” Osteoporos Int 26(1): 315-325.

Teitsson, S., J. Bobula, C. Hawes, M. Moffatt, A. Ohna and F. Borgstrom (2015). “Cost-Effectiveness of Conjugated Estrogens/Bazedoxifene for the Treatment of Vasomotor Symptoms in the United States.” Value Health 18(7): A736.

2014

Banefelt, J., A. Liede, J. Mesterton, J. Stalhammar, R. K. Hernandez, P. Sobocki and B. E. Persson (2014). “Survival and clinical metastases among prostate cancer patients treated with androgen deprivation therapy in Sweden.” Cancer Epidemiol.

Dimai, H. P., A. Svedbom, A. Fahrleitner-Pammer, H. Resch, C. Muschitz, H. Thaler, M. Szivak, K. Amrein and F. Borgstrom (2014). “Epidemiology of distal forearm fractures in Austria between 1989 and 2010.” Osteoporos Int 25(9): 2297-2306.

Henriksson, M., E. Nikolic, A. Ohna, L. Wallentin and M. Janzon (2014). “Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark.” Scand Cardiovasc J 48(3): 138-147.

Johnsen, L. G., C. Hellum, K. Storheim, O. P. Nygaard, J. I. Brox, I. Rossvoll, M. Ro, H. Andresen, S. Lydersen, O. Grundnes, M. Pedersen, G. Leivseth, G. Olafsson, F. Borgstrom and P. Fritzell (2014). “Cost-Effectiveness of Total Disc Replacement Versus Multidisciplinary Rehabilitation in Patients With Chronic Low Back Pain: A Norwegian Multicenter RCT.” Spine (Phila Pa 1976) 39(1): 23-32.

Pares-Badell, O., G. Barbaglia, P. Jerinic, A. Gustavsson, L. Salvador-Carulla and J. Alonso (2014). “Cost of disorders of the brain in Spain.” PLoS One 9(8): e105471.

Piscitelli, P., M. Brandi, H. Cawston, A. Gauthier, J. A. Kanis, J. Compston, F. Borgstrom, C. Cooper and E. McCloskey (2014). “Epidemiological burden of postmenopausal osteoporosis in Italy from 2010 to 2020: estimations from a disease model.” Calcif Tissue Int 95(5): 419-427.

Salaj, P., R. Kubes, P. Cetkovsky, I. Capova, M. Penka, P. Ovesna, J. Mesterton and P. Lindgren (2014). “Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.” Thromb Res 133(2): 162-167.

Strom, O., E. Landfeldt and G. Garellick (2014). “Residual effect after oral bisphosphonate treatment and healthy adherer effects-the Swedish adherence register analysis (SARA).” Osteoporos Int.

2013

Borgstrom, F., I. Lekander, M. Ivergard, O. Strom, A. Svedbom, V. Alekna, M. L. Bianchi, P. Clark, M. D. Curiel, H. P. Dimai, M. Jurisson, R. Kallikorm, O. Lesnyak, E. McCloskey, E. Nassonov, K. M. Sanders, S. Silverman, M. Tamulaitiene, T. Thomas, A. N. Tosteson, B. Jonsson and J. A. Kanis (2013). “The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)–quality of life during the first 4 months after fracture.” Osteoporos Int 24(3): 811-823.

Borgstrom, F., G. Olafsson, O. Strom, J. B. Tillman, D. Wardlaw, S. Boonen and C. Miltenburger (2013). “The impact of different health dimensions on overall quality of life related to kyphoplasty and non-surgical management.” Osteoporos Int 24(7): 1991-1999.

Dimai, H. P., A. Svedbom, A. Fahrleitner-Pammer, T. Pieber, H. Resch, E. Zwettler, H. Thaler, M. Szivak, K. Amrein and F. Borgstrom (2013). “Epidemiology of proximal humeral fractures in Austria between 1989 and 2008.” Osteoporos Int 24(9): 2413-2421.

Gustavsson, A., J. Bjorkman, C. Ljungcrantz, A. Rhodin, M. Rivano-Fischer, K. F. Sjolund and C. Mannheimer (2013). “Pharmacological treatment patterns in neuropathic pain–lessons from Swedish administrative registries.” Pain Med 14(7): 1072-1080.

Hubschle, L., F. Borgstrom, G. Olafsson, C. Roder, P. Moulin, A. W. Popp, F. Kulling and E. Aghayev (2013). “Real-life results of balloon kyphoplasty for vertebral compression fractures from the SWISSspine registry.” Spine J.

Kanis, J. A., F. Borgstrom, J. Compston, K. Dreinhofer, E. Nolte, L. Jonsson, W. F. Lems, E. V. McCloskey, R. Rizzoli and J. Stenmark (2013). “SCOPE: a scorecard for osteoporosis in Europe.” Arch Osteoporos 8(1-2): 144.

Karampampa, K., A. Gustavsson, E. T. van Munster, R. M. Hupperts, E. A. Sanders, J. Mostert, O. L. Sinnige, J. de Graaf, P. Pop, C. Miltenburger, M. T. Groot, M. Relleke and W. S. van der Hel (2013). “Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands.” J Med Econ 16(7): 939-950.

Lekander, I., F. Borgstrom, J. Lysholm, R. F. van Vollenhoven, S. Lindblad, P. Geborek and G. Kobelt (2013). “The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice.” Eur J Health Econ 14(6): 863-873.

Lekander, I., G. Kobelt, P. Svarvar, T. Ljung, R. van Vollenhoven and F. Borgstrom (2013). “The comparison of trial data-based and registry data-based cost-effectiveness of infliximab treatment for rheumatoid arthritis in Sweden using a modeling approach.” Value Health 16(2): 251-258.

Lindholm, C., A. Gustavsson, L. Jonsson and A. Wimo (2013). “Costs explained by function rather than diagnosis–results from the SNAC Nordanstig elderly cohort in Sweden.” Int J Geriatr Psychiatry 28(5): 454-462.

Strom, O., B. Jonsson and J. A. Kanis (2013). “Intervention thresholds for denosumab in the UK using a FRAX(R)-based cost-effectiveness analysis.” Osteoporos Int 24(4): 1491-1502.

Svedbom, A., L. Alvares, C. Cooper, D. Marsh and O. Strom (2013). “Balloon kyphoplasty compared to vertebroplasty and nonsurgical management in patients hospitalised with acute osteoporotic vertebral compression fracture: a UK cost-effectiveness analysis.” Osteoporos Int 24(1): 355-367.

2012

By, A., P. Sobocki, A. Forsgren and S. A. Silfverdal (2012). “Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model.” Clin Ther 34(1): 177-189.

Cawston, H., M. Maravic, P. Fardellone, A. Gauthier, J. A. Kanis, J. Compston, F. Borgstrom, C. Cooper and E. McCloskey (2012). “Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model.” Arch Osteoporos.

Darabi, H., K. Czene, W. Zhao, J. Liu, P. Hall and K. Humphreys (2012). “Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement.” Breast Cancer Res 14(1): R25.

Dimai, H. P., K. Redlich, M. Peretz, F. Borgstrom, U. Siebert and J. Mahlich (2012). “Economic burden of osteoporotic fractures in Austria.” Health Econ Rev 2(1): 12.

Gauthier, A., J. A. Kanis, Y. Jiang, K. Dreinhofer, M. Martin, J. Compston, F. Borgstrom, C. Cooper and E. McCloskey (2012). “Burden of postmenopausal osteoporosis in Germany: estimations from a disease model.” Arch Osteoporos.

Gustavsson, A., J. Bjorkman, C. Ljungcrantz, A. Rhodin, M. Rivano-Fischer, K. F. Sjolund and C. Mannheimer (2012). “Socio-economic burden of patients with a diagnosis related to chronic pain – Register data of 840,000 Swedish patients.” Eur J Pain 16(2): 289-299.

Gustavsson, A., J. Bjorkman, C. Ljungcrantz, A. Rhodin, M. Rivano-Fischer, K. F. Sjolund and C. Mannheimer (2012). “Pharmaceutical treatment patterns for patients with a diagnosis related to chronic pain initiating a slow-release strong opioid treatment in Sweden.” Pain 153(12): 2325-2331.

Johansson, E., A. Gustavsson, C. Miltenburger, K. Karampampa, L. Rumbach, K. Rerat and C. Thonnelier (2012). “Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France.” Mult Scler 18(2 Suppl): 17-22.

Jonsson, B., O. Strom, J. A. Eisman, A. Papaioannou, E. S. Siris, A. Tosteson and J. A. Kanis (2012). “Comment on: Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis.” Osteoporos Int 23(7): 2063-2065.

Karampampa, K., A. Gustavsson, C. Miltenburger and B. Eckert (2012). “Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries.” Mult Scler 18(2 Suppl): 7-15.

Karampampa, K., A. Gustavsson, C. Miltenburger, C. M. Kindundu and D. H. Selchen (2012). “Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada.” J Popul Ther Clin Pharmacol 19(1): e11-25.

Karampampa, K., A. Gustavsson, C. Miltenburger, S. Mora and T. Arbizu (2012). “Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain.” Mult Scler 18(2 Suppl): 35-39.

Karampampa, K., A. Gustavsson, C. Miltenburger, K. Neidhardt and M. Lang (2012). “Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Germany.” Mult Scler 18(2 Suppl): 23-27.

Karampampa, K., A. Gustavsson, C. Miltenburger, C. Teruzzi and G. Fattore (2012). “Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy.” Mult Scler 18(2 Suppl): 29-34.

Karampampa, K., A. Gustavsson, C. Miltenburger and D. Tyas (2012). “Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from the United Kingdom.” Mult Scler 18(2 Suppl): 41-45.

Landfeldt, E., B. Jablonowska, E. Norlander, K. Persdotter-Eberg, A. Thurin-Kjellberg, M. Wramsby and O. Strom (2012). “Patient preferences for characteristics differentiating ovarian stimulation treatments.” Hum Reprod 27(3): 760-769.

Landfeldt, E., O. Strom, S. Robbins and F. Borgstrom (2012). “Adherence to treatment of primary osteoporosis and its association to fractures–the Swedish Adherence Register Analysis (SARA).” Osteoporos Int 23(2): 433-443.

Lekamwasam, S., J. D. Adachi, D. Agnusdei, J. Bilezikian, S. Boonen, F. Borgstrom, C. Cooper, A. Diez Perez, R. Eastell, L. C. Hofbauer, J. A. Kanis, B. L. Langdahl, O. Lesnyak, R. Lorenc, E. McCloskey, O. D. Messina, N. Napoli, B. Obermayer-Pietsch, S. H. Ralston, P. N. Sambrook, S. Silverman, M. Sosa, J. Stepan, G. Suppan, D. A. Wahl and J. E. Compston (2012). “A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.” Osteoporos Int 23(9): 2257-2276.

Lekamwasam, S., J. D. Adachi, D. Agnusdei, J. Bilezikian, S. Boonen, F. Borgstrom, C. Cooper, A. D. Perez, R. Eastell, L. C. Hofbauer, J. A. Kanis, B. L. Langdahl, O. Lesnyak, R. Lorenc, E. McCloskey, O. D. Messina, N. Napoli, B. Obermayer-Pietsch, S. H. Ralston, P. N. Sambrook, S. Silverman, M. Sosa, J. Stepan, G. Suppan, D. A. Wahl and J. E. Compston (2012). “An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis.” Arch Osteoporos 7(1-2): 25-30.

Lekander, I., F. Borgstrom, J. Lysholm, R. F. van Vollenhoven, S. Lindblad, P. Geborek and G. Kobelt (2012). “The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice.” Eur J Health Econ.

Linde, M., A. Gustavsson, L. J. Stovner, T. J. Steiner, J. Barre, Z. Katsarava, J. M. Lainez, C. Lampl, M. Lanteri-Minet, D. Rastenyte, E. Ruiz de la Torre, C. Tassorelli and C. Andree (2012). “The cost of headache disorders in Europe: the Eurolight project.” Eur J Neurol 19(5): 703-711.

Lippuner, K., H. Johansson, F. Borgstrom, J. A. Kanis and R. Rizzoli (2012). “Cost-effective intervention thresholds against osteoporotic fractures based on FRAX(R) in Switzerland.” Osteoporos Int 23(11): 2579-2589.

Olesen, J., A. Gustavsson, M. Svensson, H. U. Wittchen and B. Jonsson (2012). “The economic cost of brain disorders in Europe.” Eur J Neurol 19(1): 155-162.

Rolfson, O., O. Strom, J. Karrholm, H. Malchau and G. Garellick (2012). “Costs related to hip disease in patients eligible for total hip arthroplasty.” J Arthroplasty 27(7): 1261-1266.

Salaj, P., M. Penka, P. Smejkal, V. Geierova, P. Ovesna, P. Brabec, P. Cetkovsky, R. Kubes, J. Mesterton and P. Lindgren (2012). “Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic.” Thromb Res.

Strom, O. and E. Landfeldt (2012). “The association between automatic generic substitution and treatment persistence with oral bisphosphonates.” Osteoporos Int 23(8): 2201-2209.

Wimo, A., A. Gustavsson, L. Jonsson, B. Winblad, M. A. Hsu and B. Gannon (2012). “Application of Resource Utilization in Dementia (RUD) instrument in a global setting.” Alzheimers Dement.

2011

Bergvall, N., P. Brinck, D. Eek, A. Gustavsson, A. Wimo, B. Winblad and L. Jonsson (2011). “Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer’s disease.” Int Psychogeriatr 23(1): 73-85.

Borgstrom, F. (2011). “Quality of life four months following a fracture – results from the ICUROS.” Osteoporos Int 22(Supplement 1 ): 91-95.

Borgstrom, F., O. Strom, M. Kleman, E. McCloskey, H. Johansson, A. Oden and J. A. Kanis (2011). “Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective.” Osteoporos Int 22(3): 955-965.

Darabi, H., K. Czene, S. Wedren, Y. Li, J. Liu, P. Hall and K. Humphreys (2011). “Genetic variation in the androgen estrogen conversion pathway in relation to breast cancer prognosticators.” Breast Cancer Res Treat 127(2): 503-509.

Darabi, H. and K. Humphreys (2011). “Single- and multi-locus association tests incorporating phenotype heterogeneity.” Hum Hered 71(1): 11-22.

Dimai, H. P., A. Svedbom, A. Fahrleitner-Pammer, T. Pieber, H. Resch, E. Zwettler, M. Chandran and F. Borgstrom (2011). “Epidemiology of hip fractures in Austria: evidence for a change in the secular trend.” Osteoporos Int 22(2): 685-692.

Fritzell, P., S. Berg, F. Borgstrom, T. Tullberg and H. Tropp (2011). “Cost effectiveness of disc prosthesis versus lumbar fusion in patients with chronic low back pain: randomized controlled trial with 2-year follow-up.” Eur Spine J 20(7): 1001-1011.

Fritzell, P., A. Ohlin and F. Borgstrom (2011). “Cost-effectiveness of balloon kyphoplasty versus standard medical treatment in patients with osteoporotic vertebral compression fracture: a Swedish multicenter randomized controlled trial with 2-year follow-up.” Spine (Phila Pa 1976) 36(26): 2243-2251.

Gauthier, A., J. A. Kanis, Y. Jiang, M. Martin, J. E. Compston, F. Borgstrom, C. Cooper and E. V. McCloskey (2011). “Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model.” Arch Osteoporos 6(1-2): 179-188.

Gauthier, A., J. A. Kanis, M. Martin, J. Compston, F. Borgstrom, C. Cooper and E. McCloskey (2011). “Development and validation of a disease model for postmenopausal osteoporosis.” Osteoporos Int 22(3): 771-780.

Gustavsson, A., P. Brinck, N. Bergvall, K. Kolasa, A. Wimo, B. Winblad and L. Jonsson (2011). “Predictors of costs of care in Alzheimer’s disease: a multinational sample of 1222 patients.” Alzheimers Dement 7(3): 318-327.

Gustavsson, A., F. Cattelin and L. Jonsson (2011). “Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants.” Alzheimers Dement 7(4): 466-473.

Gustavsson, A., L. Jonsson, J. Parmler, N. Andreasen, C. Wattmo, A. K. Wallin and L. Minthon (2011). “Disease progression and costs of care in Alzheimer’s disease patients treated with donepezil: a longitudinal naturalistic cohort.” Eur J Health Econ.

Gustavsson, A., M. Svensson, F. Jacobi, C. Allgulander, J. Alonso, E. Beghi, R. Dodel, M. Ekman, C. Faravelli, L. Fratiglioni, B. Gannon, D. H. Jones, P. Jennum, A. Jordanova, L. Jonsson, K. Karampampa, M. Knapp, G. Kobelt, T. Kurth, R. Lieb, M. Linde, C. Ljungcrantz, A. Maercker, B. Melin, M. Moscarelli, A. Musayev, F. Norwood, M. Preisig, M. Pugliatti, J. Rehm, L. Salvador-Carulla, B. Schlehofer, R. Simon, H. C. Steinhausen, L. J. Stovner, J. M. Vallat, P. V. den Bergh, J. van Os, P. Vos, W. Xu, H. U. Wittchen, B. Jonsson, J. Olesen and C. D. Group (2011). “Cost of disorders of the brain in Europe 2010.” Eur Neuropsychopharmacol 21(10): 718-779.

Johansson, H., J. A. Kanis, O. Ljunggren, O. Strom, O. Svensson and D. Mellstrom (2011). “[FRAX–model for 10-year fracture risk assessment. Support in the treatment of osteoporosis, according to preliminary Swedish guidelines].” Lakartidningen 108(7): 336-339.

Jonsson, B., O. Strom, J. A. Eisman, A. Papaioannou, E. S. Siris, A. Tosteson and J. A. Kanis (2011). “Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.” Osteoporos Int 22(3): 967-982.

Landfeldt, E., A. Lang, S. Robbins and O. Strom (2011). “Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).” Calcif Tissue Int 89(3): 234-245.

Landfeldt, E., J. Lundkvist and O. Strom (2011). “The societal burden of poor persistence to treatment of osteoporosis in Sweden.” Bone 48(2): 380-388.

Strom, O., F. Borgstrom, J. A. Kanis, J. Compston, C. Cooper, E. V. McCloskey and B. Jonsson (2011). “Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA).” Arch Osteoporos 6(1-2): 59-155.

Wimo, A., L. Jonsson, A. Gustavsson, D. McDaid, K. Ersek, J. Georges, L. Gulacsi, K. Karpati, P. Kenigsberg and H. Valtonen (2011). “The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project.” Int J Geriatr Psychiatry 26(8): 825-832.

Wittchen, H. U., F. Jacobi, J. Rehm, A. Gustavsson, M. Svensson, B. Jonsson, J. Olesen, C. Allgulander, J. Alonso, C. Faravelli, L. Fratiglioni, P. Jennum, R. Lieb, A. Maercker, J. van Os, M. Preisig, L. Salvador-Carulla, R. Simon and H. C. Steinhausen (2011). “The size and burden of mental disorders and other disorders of the brain in Europe 2010.” Eur Neuropsychopharmacol 21(9): 655-679.

2010

Borgstrom, F., O. Strom, J. Coelho, H. Johansson, A. Oden, E. McCloskey and J. A. Kanis (2010). “The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.” Osteoporos Int 21(2): 339-349.

Borgstrom, F., O. Strom, J. Coelho, H. Johansson, A. Oden, E. V. McCloskey and J. A. Kanis (2010). “The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.” Osteoporos Int 21(3): 495-505.

Borgstrom, F., O. Strom, F. Marin, A. Kutahov and O. Ljunggren (2010). “Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.” J Med Econ 13(3): 381-392.

Dimai, H. P., A. Svedbom, A. Fahrleitner-Pammer, T. Pieber, H. Resch, E. Zwettler, M. Chandran and F. Borgstrom (2010). “Reversal in the secular trend of hip fracture incidences in Austria.” Wien Klin Wochenschr 122(11-12): 380-381.

Ersek, K., T. Kovacs, A. Wimo, K. Karpati, V. Brodszky, M. Pentek, L. Jonsson, A. Gustavsson, D. McDaid, P. A. Kenigsberg, H. Valtonen and L. Gulacsi (2010). “Costs of dementia in Hungary.” J Nutr Health Aging 14(8): 633-639.

Gustavsson, A., L. Jonsson, H. Fillit, G. Johansson, A. Wimo and B. Winblad (2010). “IPECAD5–Fifth International Pharmaco-Economic Conference on Alzheimer’s Disease.” J Nutr Health Aging 14(5): 358-360.

Gustavsson, A., L. Jonsson, R. McShane, M. Boada, A. Wimo and A. S. Zbrozek (2010). “Willingness-to-pay for reductions in care need: estimating the value of informal care in Alzheimer’s disease.” Int J Geriatr Psychiatry 25(6): 622-632.

Gustavsson, A., L. Jonsson, T. Rapp, E. Reynish, P. J. Ousset, S. Andrieu, C. Cantet, B. Winblad, B. Vellas and A. Wimo (2010). “Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study.” J Nutr Health Aging 14(8): 648-654.

Ivergard, M., O. Strom, F. Borgstrom, R. T. Burge, A. N. Tosteson and J. Kanis (2010). “Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer.” Bone 47(5): 966-974.

Kanis, J. A., E. V. McCloskey, H. Johansson, A. Oden, O. Strom and F. Borgstrom (2010). “Development and use of FRAX in osteoporosis.” Osteoporos Int 21 Suppl 2: S407-413.

Kavakli, K., A. Yesilipek, B. Antmen, S. Aksu, C. Balkan, D. Yilmaz, A. Kupesiz, I. Sasmaz, P. Lindgren and J. Mesterton (2010). “The value of early treatment in patients with haemophilia and inhibitors.” Haemophilia 16(3): 487-494.

Lekander, I., F. Borgstrom, P. Svarvar, T. Ljung, C. Carli and R. F. van Vollenhoven (2010). “Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.” Int J Technol Assess Health Care 26(1): 54-61.

Mesterton, J., A. Wimo, A. By, S. Langworth, B. Winblad and L. Jonsson (2010). “Cross sectional observational study on the societal costs of Alzheimer’s disease.” Curr Alzheimer Res 7(4): 358-367.

Seeman, E., S. Boonen, F. Borgstrom, B. Vellas, J. P. Aquino, J. Semler, C. L. Benhamou, J. M. Kaufman and J. Y. Reginster (2010). “Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.” Bone 46(4): 1038-1042.

Strom, O., F. Borgstrom, M. Kleman, E. McCloskey, A. Oden, H. Johansson and J. A. Kanis (2010). “FRAX and its applications in health economics–cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example.” Bone 47(2): 430-437.

Strom, O., C. Leonard, D. Marsh and C. Cooper (2010). “Cost-effectiveness of balloon kyphoplasty in patients with symptomatic vertebral compression fractures in a UK setting.” Osteoporos Int 21(9): 1599-1608.

2009

Gustavsson, A., R. Van Der Putt, L. Jonsson and R. McShane (2009). “Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer’s disease and Dementia with Lewy bodies.” Int J Geriatr Psychiatry 24(10): 1072-1078.

Kanis, J. A., E. V. McCloskey, H. Johansson, O. Strom, F. Borgstrom and A. Oden (2009). “How to decide who to treat.” Best Pract Res Clin Rheumatol 23(6): 711-726.

Kanis, J. A., A. Oden, H. Johansson, F. Borgstrom, O. Strom and E. McCloskey (2009). “FRAX and its applications to clinical practice.” Bone 44(5): 734-743.

Lekander, I., F. Borgstrom, O. Strom, N. Zethraeus and J. A. Kanis (2009). “Cost-effectiveness of hormone therapy in the United States.” J Womens Health (Larchmt) 18(10): 1669-1677.

Lekander, I., F. Borgstrom, O. Strom, N. Zethraeus and J. A. Kanis (2009). “Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK.” Menopause Int 15(1): 19-25.

Mesterton, J., L. Jonsson, S. H. Almer, R. Befrits, I. Friis-Liby and S. Lindgren (2009). “Resource use and societal costs for Crohn’s disease in Sweden.” Inflamm Bowel Dis 15(12): 1882-1890.

Siris, E. S., P. L. Selby, K. G. Saag, F. Borgstrom, R. M. Herings and S. L. Silverman (2009). “Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.” Am J Med 122(2 Suppl): S3-13.

Strom, O., F. Borgstrom, J. A. Kanis and B. Jonsson (2009). “Incorporating adherence into health economic modelling of osteoporosis.” Osteoporos Int 20(1): 23-34.

2008

Borgstrom, F. and J. A. Kanis (2008). “Health economics of osteoporosis.” Best Pract Res Clin Endocrinol Metab 22(5): 885-900.

Kanis, J. A., J. Adams, F. Borgstrom, C. Cooper, B. Jonsson, D. Preedy, P. Selby and J. Compston (2008). “The cost-effectiveness of alendronate in the management of osteoporosis.” Bone 42(1): 4-15.

Kanis, J. A., N. Burlet, C. Cooper, P. D. Delmas, J. Y. Reginster, F. Borgstrom and R. Rizzoli (2008). “European guidance for the diagnosis and management of osteoporosis in postmenopausal women.” Osteoporos Int 19(4): 399-428.

Kanis, J. A., E. V. McCloskey, H. Johansson, O. Strom, F. Borgstrom and A. Oden (2008). “Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK.” Osteoporos Int 19(10): 1395-1408.

Lekander, I., F. Borgstrom, O. Strom, N. Zethraeus and J. A. Kanis (2008). “Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK–results based on the Women’s Health Initiative randomised controlled trial.” Bone 42(2): 294-306.

Strom, O., F. Borgstrom, N. Zethraeus, O. Johnell, L. Lidgren, S. Ponzer, O. Svensson, P. Abdon, E. Ornstein, L. Ceder, K. G. Thorngren, I. Sernbo and B. Jonsson (2008). “Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden.” Acta Orthop 79(2): 269-280.

Zethraeus, N., O. Strom, F. Borgstrom, J. A. Kanis and B. Jonsson (2008). “The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden.” Osteoporos Int 19(6): 819-827.

2007

Borgstrom, F., P. Sobocki, O. Strom and B. Jonsson (2007). “The societal burden of osteoporosis in Sweden.” Bone 40(6): 1602-1609.

Johnell, O., F. Borgstrom, B. Jonsson and J. Kanis (2007). “Latitude, socioeconomic prosperity, mobile phones and hip fracture risk.” Osteoporos Int 18(3): 333-337.

Lindgren, P., F. Borgstrom, J. Stalhammar, E. Alemao and L. Jonsson (2007). “Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs.” Int J Clin Pract 61(8): 1410-1414.

Sobocki, P., I. Lekander, F. Borgstrom, O. Strom and B. Runeson (2007). “The economic burden of depression in Sweden from 1997 to 2005.” Eur Psychiatry 22(3): 146-152.

Strom, O., F. Borgstrom, S. S. Sen, S. Boonen, P. Haentjens, O. Johnell and J. A. Kanis (2007). “Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries–an economic evaluation based on the fracture intervention trial.” Osteoporos Int 18(8): 1047-1061.

Zethraeus, N., F. Borgstrom, O. Strom, J. A. Kanis and B. Jonsson (2007). “Cost-effectiveness of the treatment and prevention of osteoporosis–a review of the literature and a reference model.” Osteoporos Int 18(1): 9-23.

2006

Borgstrom, F. (2006). “[Osteoporosis in health economic perspective].” Lakartidningen 103(40): 2963-2965.

Borgstrom, F., A. Carlsson, H. Sintonen, S. Boonen, P. Haentjens, R. Burge, O. Johnell, B. Jonsson and J. A. Kanis (2006). “The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.” Osteoporos Int 17(7): 996-1007.

Borgstrom, F., O. Johnell, J. A. Kanis, B. Jonsson and C. Rehnberg (2006). “At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis.” Osteoporos Int 17(10): 1459-1471.

Borgstrom, F., B. Jonsson, O. Strom and J. A. Kanis (2006). “An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials.” Osteoporos Int 17(12): 1781-1793.

Borgstrom, F., N. Zethraeus, O. Johnell, L. Lidgren, S. Ponzer, O. Svensson, P. Abdon, E. Ornstein, K. Lunsjo, K. G. Thorngren, I. Sernbo, C. Rehnberg and B. Jonsson (2006). “Costs and quality of life associated with osteoporosis-related fractures in Sweden.” Osteoporos Int 17(5): 637-650.

Ose, L., F. E. Skjeldestad, I. J. Bakken, A. Levorsen, E. A. Alemao, D. D. Yin, F. Borgstrom and L. Jonsson (2006). “Lipid management and cholesterol goal attainment in Norway.” Am J Cardiovasc Drugs 6(2): 121-128.

von Knorring, L., A. C. Akerblad, F. Bengtsson, A. Carlsson and L. Ekselius (2006). “Cost of depression: effect of adherence and treatment response.” Eur Psychiatry 21(6): 349-354.

2005

Kanis, J. A., F. Borgstrom, C. De Laet, H. Johansson, O. Johnell, B. Jonsson, A. Oden, N. Zethraeus, B. Pfleger and N. Khaltaev (2005). “Assessment of fracture risk.” Osteoporos Int 16(6): 581-589.

Kanis, J. A., F. Borgstrom, O. Johnell, A. Oden, D. Sykes and B. Jonsson (2005). “Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study.” Osteoporos Int 16(1): 15-25.

Kanis, J. A., F. Borgstrom, N. Zethraeus, O. Johnell, A. Oden and B. Jonsson (2005). “Intervention thresholds for osteoporosis in the UK.” Bone 36(1): 22-32.

Kanis, J. A., O. Johnell, A. Oden, F. Borgstrom, H. Johansson, C. De Laet and B. Jonsson (2005). “Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden.” Osteoporos Int 16(1): 6-14.

Lindgren, P., F. Borgstrom, J. Stalhammar, E. Alemao, D. D. Yin and L. Jonsson (2005). “Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice.” Eur J Cardiovasc Prev Rehabil 12(6): 530-534.

Zethraeus, N., F. Borgstrom, B. Jonsson and J. Kanis (2005). “Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women’s Health Initiative randomized controlled trial.” Int J Technol Assess Health Care 21(4): 433-441.

2004

Borgstrom, F., O. Johnell, B. Jonsson, N. Zethraeus and S. S. Sen (2004). “Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.” Bone 34(6): 1064-1071.

Borgstrom, F., O. Johnell, J. A. Kanis, A. Oden, D. Sykes and B. Jonsson (2004). “Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.” Pharmacoeconomics 22(17): 1153-1165.

Carlsson, A., F. Borgstrom, J. Stalhammar, E. Alemao, D. Yin and L. Jonsson (2004). “Cost of care for patients treated with lipid-lowering drugs.” Pharmacoeconomics 22 Suppl 3: 25-35.

Kanis, J. A., F. Borgstrom, O. Johnell and B. Jonsson (2004). “Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women.” Osteoporos Int 15(11): 862-871.

Kanis, J. A., O. Johnell, A. Oden, F. Borgstrom, N. Zethraeus, C. De Laet and B. Jonsson (2004). “The risk and burden of vertebral fractures in Sweden.” Osteoporos Int 15(1): 20-26.

2003

Borgstrom, F. and N. Zethraeus (2003). “[Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective].” Lakartidningen 100(1-2): 36-40.

Jonsson, L., F. Borgstrom and N. Zethraeus (2003). “[Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial].” Ugeskr Laeger 165(43): 4112-4116.

Kobelt, G., F. Borgstrom and A. Mattiasson (2003). “Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia.” BJU Int 91(3): 190-195.